CLRB
Cellectar Biosciences Inc.
$2.86
+$0.04(+1.42%)
42
Overall
60
Value
25
Tech
--
Quality
Market Cap
$10.69M
Volume
59.60K
52W Range
$2.71 - $48.90
Target Price
$47.00
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $-404.1K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Total Revenue | $-404.1K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $-404.1K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $8.6M | $9.4M | $13.6M | $11.7M | $14.2M | $15.3M | $24.1M | $28.8M | $39.0M | $51.8M | ||
| Research & Development | $5.2M | $4.8M | $9.5M | $6.8M | $9.0M | $10.1M | $17.6M | $19.2M | $27.3M | $26.1M | ||
| Research Expense | $5.2M | $4.8M | $9.5M | $6.8M | $9.0M | $10.1M | $17.6M | $19.2M | $27.3M | $26.1M | ||
| Selling, General & Administrative | $3.4M | $4.7M | $4.1M | $4.8M | $5.2M | $5.1M | $6.5M | $9.6M | $11.7M | $25.6M | ||
| General & Administrative Expenses | $3.4M | $4.7M | $4.1M | $4.8M | $5.2M | $5.1M | $6.5M | $9.6M | $11.7M | $25.6M | ||
| Salaries & Wages | -- | -- | $-758.8K | $-721.2K | $-866.8K | $467.5K | $1.1M | $1.5M | $2.4M | $4.3M | ||
| Depreciation & Amortization | -- | -- | $-1.5M | $-82.3K | $-132.8K | -- | $150.0K | $148.0K | $192.0K | $292.0K | ||
| Depreciation & Amortization | -- | -- | $-1.5M | $-82.3K | $-132.8K | -- | $150.0K | $148.0K | $192.0K | $292.0K | ||
| Other Operating Expenses | -- | -- | -- | -- | -- | -- | $113.0K | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-8.6M | $-9.4M | $-13.6M | $-11.7M | $-14.2M | $-15.3M | $-24.1M | $-28.8M | $-39.0M | $-51.8M | ||
| EBITDA | $-5.1M | $-5.8M | $-12.0M | $-13.2M | $-14.0M | $-15.1M | $-24.0M | $-28.7M | $-42.6M | $-44.2M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $-4.0K | $-1.5K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Intinc | $-405.0K | $7.9K | $16.6K | $29.7K | $42.7K | $10.9K | $2.3K | $152.5K | $387.1K | $1.2M | ||
| Net Non-Operating Interest Income/Expense | $-405.0K | $7.9K | $16.6K | $29.7K | $42.7K | $10.9K | $2.3K | $152.5K | $387.1K | $1.2M | ||
| Gain on Sale of Securities | $3.7M | $3.3M | $22.1K | $62.0K | $43.0K | -- | $6.6K | -- | -- | -- | ||
| Other Income/Expense | $-3.7M | $-3.3M | $-22.1K | $-62.0K | $-43.0K | $-185.3K | $-6.6K | -- | $3.8M | $-13.8M | ||
| Other Special Charges | -- | -- | -- | -- | -- | $185.3K | -- | -- | $-3.8M | $13.8M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $203.6K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Special Income Charges | $-203.6K | -- | -- | $-1.7M | -- | -- | -- | -- | -- | $-146.0K | ||
| Impairment of Capital Assets | -- | -- | -- | $1.7M | -- | -- | -- | -- | -- | $146.0K | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-5.5M | $-6.2M | $-13.6M | $-13.2M | $-14.1M | $-15.3M | $-24.1M | $-28.8M | $-42.8M | $-44.5M | ||
| Pre-Tax Income | $-5.5M | $-6.2M | $-13.6M | $-13.2M | $-14.1M | $-15.1M | $-24.1M | $-28.7M | $-42.8M | $-44.5M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | -- | -- | -- | $-4.9M | $-8.2M | $-60.0K | $-60.0K | $66.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-5.5M | $-6.2M | $-13.6M | $-13.2M | $-14.1M | $-15.1M | $-24.1M | $-28.6M | $-42.8M | $-44.6M | ||
| Net Income (Continuing Operations) | $-5.5M | $-6.2M | $-13.6M | $-13.2M | $-14.1M | $-15.1M | $-24.1M | $-28.6M | $-42.8M | $-44.6M | ||
| Net Income (Discontinued Operations) | $-5.5M | $-6.2M | $-13.6M | $-13.2M | $-14.1M | $-15.1M | $-24.1M | $-28.6M | $-42.8M | $-44.6M | ||
| Net Income (Common Stockholders) | $-5.5M | $-9.4M | $-15.0M | $-15.5M | $-14.1M | $-15.1M | $-24.1M | $-28.6M | $-42.8M | $-44.6M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-32.3M | -- | -- | $-43.9M | ||
| TOTALS | ||||||||||||
| Total Expenses | $8.6M | $9.4M | $13.6M | $11.7M | $14.2M | $15.3M | $24.1M | $28.8M | $39.0M | $51.8M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $260 | $1.5K | $4.7K | $9.9K | $25.6K | $66.0K | $185.1K | $235.2K | $407.4K | $36.6M | ||
| Average Shares Outstanding (Diluted) | $260 | $1.5K | $4.2K | $8.4K | $25.5K | $66.0K | $185.1K | $235.2K | $407.4K | $37.1M | ||
| Shares Outstanding | $286 | $4.3K | $5.8K | $15.9K | $31.3K | $168.3K | $203.7K | $324.7K | $3.2M | $46.1M | ||
| Basic EPS | -- | -- | -- | -- | -- | $-228 | $-129 | $-121.5 | $-93.3 | $-1.22 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-228 | $-129 | $-121.5 | $-93.3 | $-1.22 | ||
| Diluted EPS | $-21.1K | $-4.1K | $-3.2K | $-1.6K | $-552 | $-228 | $-228 | $-121.5 | $-93.3 | $-1.4 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-228 | $-121.5 | $-93.3 | $-1.4 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | -- | $3.2M | $1.4M | $2.2M | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $3.4M | $4.7M | $4.1M | $4.8M | $5.2M | $5.1M | $6.5M | $9.6M | $11.7M | $25.6M | ||
| Otherunder Preferred Stock Dividend | -- | $3.2M | $1.4M | $2.2M | -- | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | -- | $3.2M | $1.4M | $2.2M | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $3.4M | $4.7M | $4.1M | $4.8M | $5.2M | -- | -- | $-11.8K | $-11.8K | -- | ||
| Restruct | $203.6K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CLRB | $2.86 | +1.4% | 59.60K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Cellectar Biosciences Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW